IMARC Group has recently released a new research study titled “United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region, 2025-2033” which offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Market Overview

The United States biologics market size was valued at USD 190.3 Billion in 2024 and is forecast to reach USD 371.0 Billion by 2033, registering a CAGR of 7.4% during 2025-2033. The market growth is driven by rapid adoption of bioprocessing technologies, expansion of biosimilars to address affordability, and rising integration of AI in drug discovery and manufacturing. These advancements enhance innovation, reduce costs, and improve access to advanced therapies.

Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

United States Biologics Market Key Takeaways

  • Current Market Size: USD 190.3 Billion in 2024
  • CAGR: 7.4% (2025-2033)
  • Forecast Period: 2025-2033
  • The market is propelled by biotechnology advancements enabling monoclonal antibodies, gene therapies, and biosimilars.
  • Chronic diseases affect about 129 million Americans, driving demand for innovative biologics.
  • Supportive FDA frameworks such as fast-track approvals accelerate new therapy introduction.
  • Growing investments in R&D by biotech and pharmaceutical firms foster next-generation treatments.
  • Increasing demand for biosimilars boosts competition and market share.

Sample Request Link: https://www.imarcgroup.com/united-states-biologics-market/requestsample

To get more information on this market,  Request Sample

United States Biologics Market Growth Factors

The United States biologics market growth is primarily driven by continual advancements in biotechnology. Therapeutic innovations like monoclonal antibodies, gene therapies, and biosimilars are addressing complex diseases and unmet medical needs. Chronic diseases, affecting an estimated 129 million Americans, require novel, effective biologics, driving considerable demand. The chronic disease burden accounts for 90% of the annual USD 4.1 Trillion healthcare expenditure, highlighting the critical role of biologics therapies in reducing healthcare costs and improving quality of life.

Another growth driver is the rapid adoption of advanced bioprocessing technologies, such as single-use bioreactors, continuous manufacturing, and high-throughput screening systems. These innovations have improved production efficiency, scalability, and cost-effectiveness while maintaining high-quality standards. For example, Rentschler Biopharma's Milford facility doubled capacity with four 2,000L single-use bioreactors. Automation and digital tools optimize bioprocessing with consistent output and minimal errors, attracting significant biopharmaceutical investments in facility upgrades.

The growing biosimilars market also drives growth by addressing affordability issues. Biosimilars provide cost-effective alternatives to branded biologics with similar efficacy and safety, increasing patient accessibility. The FDA's Biosimilar Approval Pathway facilitates market entry and competition, lowering treatment costs. Pharmaceutical companies invest heavily in biosimilar R&D, anticipating patent expirations for original biologics. As acceptance widens among healthcare providers and patients, biosimilars foster innovation and expand market share.

United States Biologics Market Segmentation

Analysis by Source:

  • Microbial: Efficient hosts for recombinant proteins, enzymes, and vaccines; known for rapid growth, cost-effectiveness; includes E. coli and yeast systems.
  • Mammalian: Critical for complex biologics like monoclonal antibodies and cell therapies; offers superior post-translational modifications; dominated by CHO cells.
  • Others

Analysis by Product:

  • Monoclonal Antibodies: Used widely for cancer, autoimmune diseases and infections; targeted therapies with fewer side effects; includes innovations like antibody-drug conjugates.
  • Vaccines: Growing rapidly due to mRNA technology and pandemic preparedness; includes COVID-19 vaccines; expanding research in cancer and personalized vaccines.
  • Recombinant Proteins: Used for diabetes, anemia and growth disorders; enhancements in protein engineering and biosimilars improve efficacy and affordability.
  • Antisense, RNAi and Molecular Therapy
  • Others

Analysis by Disease:

  • Oncology: Leading segment driven by cancer prevalence; employs monoclonal antibodies and immune checkpoint inhibitors; strong growth in CAR-T and personalized medicine.
  • Immunological Disorders: Strong growth in chronic diseases like rheumatoid arthritis and psoriasis; therapies include cytokine inhibitors and TNF blockers; biosimilars enhance access.
  • Cardiovascular Disorders: Increasing use of biologics like PCSK9 inhibitors for cholesterol regulation; growth in rare cardiovascular biologics and regenerative therapies.
  • Hematological Disorders
  • Others

Analysis by Manufacturing:

  • Outsourced: Increasing reliance on CROs and CMOs for cost-efficient production; access to advanced technology and scalability; supports biosimilars and gene therapies.
  • In-House: Maintains control over processes, quality and IP; large firms invest in advanced facilities; allows flexibility and sustained innovation despite higher costs.

Regional Analysis:

  • Northeast: Driven by biotech and pharmaceutical hubs in Massachusetts and New York; strong infrastructure and R&D support innovation.
  • Midwest: Rapid growth in manufacturing with focus in Illinois and Indiana; investment in technologies and government incentives.
  • South: Presence of major biopharma companies in North Carolina and Texas; increased clinical trials and life sciences investments.
  • West: Innovation leader, especially California; strong in CAR-T therapies, mRNA vaccines, personalized medicine, and sustainability; supported by venture capital.

Regional Insights

The biologics market is dominated by the West region, particularly California, known for cutting-edge biologics research including CAR-T cell therapies and mRNA vaccines. Strong venture capital funding and collaboration between startups and academic institutions bolster innovation. The West leads in personalized medicine and sustainability, shaping the future of healthcare in the U.S. The Northeast, Midwest, and South hold strategic importance with robust R&D, manufacturing capabilities, and clinical trial activity, respectively.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

Recent Developments & News

  • On September 27, 2024, the FDA approved Dupixent (dupilumab) as the first biologic treatment for inadequately controlled COPD with an eosinophilic phenotype, reducing exacerbations by up to 34% and improving lung function.
  • On February 29, 2024, Biocon Biologics Ltd signed a settlement and license agreement with Janssen Biotech to commercialize Bmab 1200, a biosimilar to Stelara (Ustekinumab), in the U.S. starting February 2025, pending FDA approval. Stelara was a USD 7 Billion drug in 2023 for immune diseases like psoriasis.

Key Players

  • Galapagos NV
  • Blood Centers of America
  • Rentschler Biopharma
  • Sobi
  • Biocon Biologics Ltd
  • Janssen Biotech

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302